Meriofert Pfs (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Both hormones bind to specific receptors on ovarian or testicular cells. FSH stimulates follicular growth, estrogen production and ovulation, while LH triggers luteinisation, progesterone secretion and testosterone synthesis, thereby restoring normal reproductive hormone cycles.

The dose of Meriofert Pfs is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s clinical condition, response to therapy and monitoring results.

Meriofert Pfs is intended for use before conception to achieve pregnancy. It is not recommended during pregnancy, and safety during breastfeeding has not been established. Clinicians should evaluate risks and benefits before prescribing.

To order, submit an enquiry on the Meriofert Pfs product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Meriofert Pfs combines LH and FSH in a single injectable, whereas some alternatives provide only one hormone or require separate preparations. The combined formulation can simplify dosing schedules and may improve patient convenience, but choice depends on individual treatment protocols and physician preference.

Meriofert Pfs should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The medication is supplied as an injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional following aseptic technique and the dosing schedule prescribed by the treating physician.

Serious risks include severe ovarian hyperstimulation syndrome, thromboembolic events, allergic reactions such as anaphylaxis, and the possibility of multiple pregnancy. Patients should be closely monitored for these complications during treatment.

Meriofert Pfs is contraindicated in individuals with known hypersensitivity to gonadotropins, in patients with active ovarian cysts or severe ovarian disease, and in those with estrogen‑sensitive malignancies unless specifically advised by a specialist.